Gapping up
Select ETFs showing strength:
- QQQ +1.1%, DIA +1%, IWM +1%, SPY +0.8%
Other news:
- ODT +10.3% (announced positive top-line results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer)
- TRVN +9.6% (announced Imperial College London has initiated a proof-of-concept study for TRV027 in COVID-19 patients)
- TLSA +5.6% (receives patent methods and use of Anti-IL-6/IL-6 receptor monoclonal antibodies as prophylactic and therapeutic interventions for COVID-19)
- PLX +3.9% (announces completion of the treatment period for its Phase III Bright clinical trial of pegunigalsidase alfa (prx-102) for the proposed treatment of fabry disease) SYNA +3.6% (positive article in Barrons)
- AZN +3.4% (President Trump is considering bypassing regulatory standards to fast track AZN's UK coronavirus vaccine)
- GM +3.3% (positive article in Barrons)
- W +1.9% (announces $700 mln stock repurchase authorization -- 8K filing)
- CWH +1.6% (declares regular and special dividend)
- UHAL +1.4% (declares special cash dividend on common stock of $0.50/share)
- LOW +1.2% (increases quarterly cash dividend to $0.60/share from $0.55/share)
- TJX +1.2% (positive article in Barrons)
- MSFT +1% (CNBC report co is signing deals with foreign govts to offer cloud-infrastructure packages)
Analyst comments:
- LI +5.2% (added to Conviction Buy List at Goldman)
- BLDP +4.9% (initiated with an Outperform at Bernstein)
- ALVR +3% (initiated with an Overweight at Morgan Stanley)
- EL +1.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- QGEN +1.4% (upgraded to Buy from Neutral at Citigroup)
- MFA +1.1% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities)